IP Library Granted Patent US 8,574,564
Granted Patent B2
US 8,574,564 · App. 12/576,086 · Granted Nov 5, 2013

Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

Inventors: Wolfgang A. Renner (Kilchberg, CH); Martin F. Bachmann (Seuzach, CH); Indulis Cielens (Riga, LV); Conrad Johannes Coester (Neuhof, DE); Klaus Dietmeier (Zürich, CH); Sebastian Fuchs (Munich, DE); Vania Manolova (Zürich, CH); Patrik Maurer (Winterthur, CH); Paul Pumpens (Riga, LV); Regina Renhofa (Riga, LV); Alain Tissot (Zürich, CH); Yu Zou (Birmensdorf, CH)
Assignee: Cytos Biotechnology AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,574,564
App. No.
12/576,086
Granted
Nov 5, 2013
Kind
B2
Abstract

The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.

Claims (24)

1. A method of treating a hypersensitivity in an animal, wherein said hypersensitivity is allergy or asthma, wherein said method comprises introducing a composition into said animal, and wherein said composition comprises:

(a) virus-like particle of an RNA bacteriophage Qβ; and

(b) an unmethylated CpG-containing oligonucleotide consisting essentially of the sequence GGGGGGGGGG GACGATCGTC GGGGGGGGGG (SEQ ID NO:27); wherein said virus-like particle of an RNA bacteriophage Qβ is packaged with said unmethylated CpG-containing oligonucleotide, wherein said composition does not comprise an allergen, and wherein introduction of said composition treats said hypersensitivity in said animal.

2. The method of claim 1 , wherein said unmethylated CpG-containing oligonucleotide consists exclusively of phosphodiester bound nucleotides.

3. The method of claim 1 , wherein said hypersensitivity is asthma.

4. The method of claim 3 , wherein said asthma is IgE-mediated asthma.

5. The method of claim 1 , wherein said hypersensitivity is an IgE-mediated allergy (type I allergy).

6. The method of claim 5 , wherein said IgE-mediated allergy is pollen allergy or house dust allergy.

7. The method of claim 1 , wherein said animal is a human.

8. The method of claim 1 , wherein said method does not comprise introducing an allergen to said animal.

9. The method of claim 1 , wherein an allergen is not introduced in said animal for at least eight weeks before and at least eight weeks after said introduction of said composition in said animal.

10. The method of claim 1 , wherein said virus-like particle of an RNA bacteriophage Qβ consists of coat proteins having the amino acid sequence of SEQ ID NO:3.

11. A method of treating a hypersensitivity in an animal, wherein said hypersensitivity is allergy or asthma, wherein said method comprises introducing a composition into said animal, and wherein said composition comprises:

(a) virus-like particle of an RNA bacteriophage Qβ; and

(b) an unmethylated CpG-containing oligonucleotide consisting essentially of the sequence GGGGGGGGGG GACGATCGTC GGGGGGGGGG (SEQ ID NO:27); wherein said virus-like particle of an RNA bacteriophage Qβ is packaged with said unmethylated CpG-containing oligonucleotide, and wherein said method does not comprise co-administering an allergen to said animal, and wherein introduction of said composition treats said hypersensitivity in said animal.

12. The method of claim 11 , wherein said animal is a human.

13. The method of claim 12 , wherein said virus-like particle of an kNA bacteriophage Qβ consists of coat proteins having the amino acid sequence of SEQ ID NO:3.

14. The method of claim 13 , wherein said unmethylated CpG-containing oligonucleotide consists exclusively of phosphodiester bound nucleotides.

15. The method of claim 14 , wherein said hypersensitivity is asthma.

16. The method of claim 15 , wherein said asthma is IgE-mediated asthma.

17. The method of claim 16 , wherein said method does not comprise introducing an allergen to said animal.

18. The method of claim 16 , wherein an allergen is not introduced in said animal for at least one week before and at least one week after said introduction of said composition in said animal.

19. The method of claim 16 , wherein an allergen is not introduced in said animal for at least four weeks before and at least four weeks after said introduction of said composition in said animal.

20. The method of claim 16 , wherein an allergen is not introduced in said animal for at least eight weeks before and at least eight weeks after said introduction of said composition in said animal.

Assignments (4)
SECURITY AGREEMENT Recorded May 25, 2012
From: CYTOS BIOTECHNOLOGY AG
To: VENBIO GLOBAL STRATEGIC FUND L.P.
Reel/Frame 028275/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: RENNER, WOLFGANG A.; BACHMANN, MARTIN F.; CIELENS, INDULIS; DIETMEIER, KLAUS; MANOLOVA, VANIA; MAURER, PATRIK; PUMPENS, PAUL; RENHOFA, REGINA; TISSOT, ALAIN; ZOU, YU
To: CYTOS BIOTECHNOLOGY AG
Reel/Frame 027748/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: LUDWIG-MAXIMILIANS-UNIVERSITAT-MUNCHEN
To: CYTOS BIOTECHNOLOGY AG
Reel/Frame 027748/0801 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: COESTER, CONRAD JOHANNES; FUCHS, SEBASTIAN
To: LUDWIG-MAXIMILIANS-UNIVERSITAT-MUNCHEN
Reel/Frame 027748/0807 →
Continuity (4)
Continuation 11638664 · Dec 14, 2006
Provisional Application 60750042 · Dec 14, 2005
Provisional Application 60812592 · Jun 12, 2006
Related Publication 20100303846A1 · Dec 2, 2010